title: Lack of any relationship between chemotherapy toxicity in non-small cell lung cancer cases and polymorphisms in XRCC1 codon 399 or XPD codon 751.
abstract: OBJECTIVE
  To examine the association between genetic polymorphisms (at XRCC1codon 399 or XPD codon 751) and chemotherapy related toxicities of non-small cell lung cancer.
  
  
  METHODS
  One hundred and fifteen patients with histologically or cytologically confirmed stage IIIB and IV NSCLC recruited from Department of Chemotherapy of Jiangsu Cancer Hospital and Research Institute from 2005 to 2008, to evaluated the occurrence of chemotherapy related toxicities and the association with single nucleotide polymorphisms in XRCC1codon 399 or XPD codon 751.
  
  
  RESULTS
  No significant association was observed between grade 0 or grade 1-4 overall toxicity and XRCC1 codon 399 (odds ratio=1.40, 95% confidence interval,0.73-2.66; adjusted odds ratio =1.43, 95% confidence interval,0.71-2.88), or XPD codon 751 genetic polymorphisms (odds ratio =0.87, 95% confidence interval,0.33-2.26; adjusted odds ratio=0.74, 95% confidence interval,0.26-2.13); similar results were found between hematologic, hepatic, gastrointestinal toxicities and XRCC1 399 or XPD 751 genetic polymorphisms.
  
  
  CONCLUSIONS
  No statistically significant association was found between either XRCC1codon 399 or XPD codon 751 genetic polymorphisms and chemotherapy related toxicities.
authors.affiliation: Department of Chemotherapy, Jiangsu Cancer Hospital and Research Institute, Nanjing, China. huangxinen06@yahoo.com.cn
authors.forename: Yan
authors.initials: Y
authors.lastname: Li
authors.forename: Xin-En
authors.initials: XE
authors.lastname: Huang
authors.forename: Guang-Fu
authors.initials: GF
authors.lastname: Jin
authors.forename: Hong-Bin
authors.initials: HB
authors.lastname: Shen
authors.forename: Lin
authors.initials: L
authors.lastname: Xu
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy / Q000235:genetics / Q000556:secondary; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D018287:Carcinoma, Large Cell / Q000188:drug therapy / Q000235:genetics / Q000556:secondary; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000235:genetics / Q000556:secondary; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy / Q000235:genetics / Q000556:secondary; D002945:Cisplatin / Q000008:administration & dosage; D003062:Codon / Q000235:genetics*; D004273:DNA, Neoplasm / Q000235:genetics; D004268:DNA-Binding Proteins / Q000235:genetics*; D003841:Deoxycytidine / Q000008:administration & dosage / Q000031:analogs & derivatives; D000077143:Docetaxel; D005260:Female; D005500:Follow-Up Studies; D005838:Genotype; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000235:genetics / Q000473:pathology; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D017239:Paclitaxel / Q000008:administration & dosage; D016133:Polymerase Chain Reaction; D012150:Polymorphism, Restriction Fragment Length; D020641:Polymorphism, Single Nucleotide / Q000235:genetics*; D015996:Survival Rate; D043823:Taxoids / Q000008:administration & dosage; D016896:Treatment Outcome; D000076105:X-ray Repair Cross Complementing Protein 1; D051759:Xeroderma Pigmentosum Group D Protein / Q000235:genetics*; D000093542:Gemcitabine
chemical_list: D003062:Codon; D004273:DNA, Neoplasm; D004268:DNA-Binding Proteins; D043823:Taxoids; D000076105:X-ray Repair Cross Complementing Protein 1; C000619371:XRCC1 protein, human; D003841:Deoxycytidine; D000077143:Docetaxel; D051759:Xeroderma Pigmentosum Group D Protein; C497292:ERCC2 protein, human; D017239:Paclitaxel; D002945:Cisplatin; D000093542:Gemcitabine